Technical Analysis for PRRUF - Immutep Limited

Grade Last Price % Change Price Change
grade A 0.09 -59.09% -0.1300
PRRUF closed down 59.09 percent on Wednesday, April 22, 2020, on 33 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Flat
Historical PRRUF trend table...

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Gapped Down Weakness 0.00%
Narrow Range Bar Range Contraction -59.09%
New 52 Week Closing High Bullish -59.09%
Narrow Range Bar Range Contraction -59.09%
New 52 Week High Strength -59.09%
Stochastic Reached Overbought Strength -59.09%
Older signals for PRRUF ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. The company's lead product candidate is eftilagimod alpha (efti) with KEYTRUDA therapy, an antigen presenting cell activator, which is in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer, as well as in a Phase I combination therapy trial in metastatic melanoma. Its other products include IMP731, a LAG-3 depleting antibody, which is in a Phase I clinical trial for use in autoimmune diseases; IMP701, a LAG-3 antagonist antibody that is in a Phase I/II clinical trial, which is used for the treatment of cancer; and IMP761, an agonist of LAG-3 for treating autoimmune diseases. The company has operations in Europe, Australia, and the United States. Immutep Limited has a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc., to evaluate the combination of efti with avelumab, a human anti-PD-L1 antibody, in patients with advanced solid malignancies; and partnerships with GlaxoSmithKline, Novartis, and EOC Pharma for the development of LAG-3 product candidates. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited is headquartered in Sydney, Australia.
Biotechnology Cancer Clinical Medicine Drugs Treatment Of Cancer Autoimmune Diseases Cancer Treatments Alpha Monoclonal Antibodies Antineoplastic Drugs Biological Products Merck Metastatic Breast Cancer Metastatic Melanoma Immunotherapeutic Products Immutep

Is PRRUF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.22
52 Week Low 0.01
Average Volume 30,340
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0559
10-Day Moving Average 0.0900
Average True Range 0.0318
ADX 0.0
+DI 52.8697
-DI 43.1690
Chandelier Exit (Long, 3 ATRs ) 0.1246
Chandelier Exit (Short, 3 ATRs ) 0.1054
Upper Bollinger Band 0.1984
Lower Bollinger Band -0.0866
Percent B (%b) 0.62
BandWidth 509.8390
MACD Line 0.0460
MACD Signal Line 0.0246
MACD Histogram 0.0214
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0900
Resistance 3 (R3) 0.0900 0.0900 0.0900
Resistance 2 (R2) 0.0900 0.0900 0.0900 0.0900
Resistance 1 (R1) 0.0900 0.0900 0.0900 0.0900 0.0900
Pivot Point 0.0900 0.0900 0.0900 0.0900 0.0900
Support 1 (S1) 0.0900 0.0900 0.0900 0.0900 0.0900
Support 2 (S2) 0.0900 0.0900 0.0900 0.0900
Support 3 (S3) 0.0900 0.0900 0.0900
Support 4 (S4) 0.0900